Alberta adds Zolgensma to drug coverage program

olgensma, a one-time gene therapy used to treat spinal muscular atrophy, will change the lives of eligible Alberta children as it is now part of the 5are Diseases Drug Coverage 3rogram.

Interim access to olgensma was provided by Alberta’s government from -anuary to -une while national drug review, approval and price negotiation processes were being completed. The panCanadian 3harmaceutical Alliance subseTuently reached a long-term pricing agreement with the manufacturer in 2ctober.

“We are extremely pleased that a long-term agreement with the manufacturer has been reached and we are now able to provide this life-changing treatment to Alberta children on a permanent basis. Treating spinal muscular atrophy early provides children with important developmental support and the best possible health outcomes.” -ason Copping, Minister of ealth

“Muscular Dystrophy Canada is pleased this gene therapy will be offered to children in Alberta who are diagnosed with spinal muscular atrophy. Through early diagnosis and treatment, we can give these children a better start and providing access to this therapy is an important part of that care.” 6tacey Lintern, CE2, Muscular Dystrophy Canada

Alberta’s government also provides coverage for the drug 6pinra a for patients with spinal muscular atrophy who meet the eligibility criteria through the Alberta Drug Benefit List.

In addition, work is underway to pilot a newborn screening test for spinal muscular atrophy and subseTuently incorporate the test into Alberta’s 1ewborn Metabolic 6creening 3rogram.